N-(2-萘基)脲 | 13114-62-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: N-(2-萘基)脲
• 英文名称: 2-naphthylcarbamide
• 英文别名: 2-naphthylurea；N-β-Naphthylharnstoff；[2]Naphthyl-harnstoff；β-Naphthyl-harnstoff；2-naphthalenyl-urea；naphthalen-2-ylurea
• CAS: 13114-62-0
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD00021598
• 分子量: 186.213
• InChiKey: MRSYBIDUQWAWBO-UHFFFAOYSA-N

物化性质

• 熔点：
  219°C
• 沸点：
  320.7°C (rough estimate)
• 密度：
  1.1458 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  1

SDS

Version 1.2
Regulation (EC) No 1907/2006

---

1 - Product and Company Information

---

Product Name 1-(2-NAPHTHYL)UREA

---

2 - Hazards Identification

---

3 - Composition/Information on Ingredients

---

Product Name CAS # EC no Annex I
Index Number
1-(2-NAPHTHYL)UREA None None None

---

4 - First Aid Measures

---

AFTER INHALATION
If inhaled, remove to fresh air. If not breathing give
artificial respiration. If breathing is difficult, give oxygen.
AFTER SKIN CONTACT
In case of contact, immediately wash skin with soap and copious
amounts of water.
AFTER EYE CONTACT
In case of contact, immediately flush eyes with copious amounts
of water for at least 15 minutes.
AFTER INGESTION
If swallowed, wash out mouth with water provided person is
conscious. Call a physician.

---

5 - Fire Fighting Measures

---

EXTINGUISHING MEDIA
Suitable: Water spray. Carbon dioxide, dry chemical powder, or
appropriate foam.
SPECIAL RISKS
Specific Hazard(s): Emits toxic fumes under fire conditions.
ALDRICH www.molbase.com
SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS
Wear self-contained breathing apparatus and protective clothing
to prevent contact with skin and eyes.

---

6 - Accidental Release Measures

---

PROCEDURE(S) OF PERSONAL PRECAUTION(S)
Wear respirator, chemical safety goggles, rubber boots, and
heavy rubber gloves.
METHODS FOR CLEANING UP
Sweep up, place in a bag and hold for waste disposal. Avoid
raising dust. Ventilate area and wash spill site after material
pickup is complete.

---

7 - Handling and Storage

---

HANDLING
Directions for Safe Handling: Avoid inhalation. Avoid contact
with eyes, skin, and clothing. Avoid prolonged or repeated
exposure.
STORAGE
Conditions of Storage: Keep tightly closed. Store in a cool dry
place.

---

8 - Exposure Controls / Personal Protection

---

ENGINEERING CONTROLS
Safety shower and eye bath. Mechanical exhaust required.
GENERAL HYGIENE MEASURES
Wash thoroughly after handling. Wash contaminated clothing before
reuse.
PERSONAL PROTECTIVE EQUIPMENT
Respiratory Protection: Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US)
or CEN (EU). Respiratory protection is not required. Where
protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks.
Hand Protection: Compatible chemical-resistant gloves.
Eye Protection: Chemical safety goggles.

---

9 - Physical and Chemical Properties

---

Appearance Physical State: Solid
Property Value At Temperature or Pressure
pH N/A
BP/BP Range N/A
MP/MP Range N/A
Flash Point N/A
Flammability N/A
Autoignition Temp N/A
Oxidizing Properties N/A
Explosive Properties N/A
Explosion Limits N/A
Vapor Pressure N/A
ALDRICH www.molbase.com
Partition Coefficient N/A
Viscosity N/A
Vapor Density N/A
Saturated Vapor Conc. N/A
Evaporation Rate N/A
Bulk Density N/A
Decomposition Temp. N/A
Solvent Content N/A
Water Content N/A
Surface Tension N/A
Conductivity N/A
Miscellaneous Data N/A
Solubility N/A

---

10 - Stability and Reactivity

---

STABILITY
Stable: Stable.
Materials to Avoid: Strong oxidizing agents.
HAZARDOUS DECOMPOSITION PRODUCTS
Hazardous Decomposition Products: Carbon monoxide, Carbon dioxide,
Nitrogen oxides.
HAZARDOUS POLYMERIZATION
Hazardous Polymerization: Will not occur

---

11 - Toxicological Information

---

SIGNS AND SYMPTOMS OF EXPOSURE
To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
ROUTE OF EXPOSURE
Skin Contact: May cause skin irritation.
Skin Absorption: May be harmful if absorbed through the skin.
Eye Contact: May cause eye irritation.
Inhalation: May be harmful if inhaled.
Ingestion: Harmful if swallowed.

---

12 - Ecological Information

---

No data available.

---

13 - Disposal Considerations

---

SUBSTANCE DISPOSAL
Dissolve or mix the material with a combustible solvent and burn
in a chemical incinerator equipped with an afterburner and
scrubber. Observe all federal, state, and local environmental
regulations.

---

14 - Transport Information

---

15 - Regulatory Information

---

Caution: Substance not yet fully tested (EU).
COUNTRY SPECIFIC INFORMATION
ALDRICH www.molbase.com
Germany
WGK: 3
Self-Classification

---

16 - Other Information

---

WARRANTY
The above information is believed to be correct but does not
purport to be all inclusive and shall be used only as a guide. The
information in this document is based on the present state of our
knowledge and is applicable to the product with regard to
appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Inc.,
shall not be held liable for any damage resulting from handling or
from contact with the above product. See reverse side of invoice
or packing slip for additional terms and conditions of sale.
Copyright 2010 Co. License granted to make
unlimitedpaper copies for internal use only.
DISCLAIMER
For R&D use only. Not for drug, household or other uses.
ALDRICH www.molbase.com

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(2-萘基)脲 生成 1,3-二萘-2-基脲
  参考文献：
  名称：

  Walther; Wlodkowski, Journal fur praktische Chemie (Leipzig 1954), 1899, vol. <2> 59, p. 269

  摘要：

  DOI：
• 作为产物：
  描述：

  2-萘基异氰酸酯 在 氨 作用下， 生成 N-(2-萘基)脲
  参考文献：
  名称：

  The Preparation and Bacteriostatic Activity of Substituted Ureas

  摘要：

  DOI：

  10.1021/ja01562a053

文献信息

• New Palladium-Catalyzed Domino Reaction with Intramolecular Ring Closure of an<i>N</i>-(2-Chloro-3-heteroaryl)arylamide: First Synthesis of Oxazolo[4,5-<i>b</i>]pyrazines
  作者：Charles S. Demmer、Jacob C. Hansen、Jan Kehler、Lennart Bunch

  DOI：10.1002/adsc.201300845

  日期：2014.3.24

  Pd(II)‐catalyzed domino reaction comprising the first Pd(II)‐assisted intramolecular cyclization of an N‐(2‐chloro‐3‐heteroaryl)arylamide and validate its value by application to the first synthesis of 2‐substituted oxazolo[4,5‐b]pyrazines. We demonstrate that a bidentate phosphorus ligand as well as the presence of an aromatic nitrogen atom is required for the domino reaction to proceed. The robustness

  新型平面杂环的合成是基础研究的核心，因为这种支架构成了重要的不同研究领域的重要组成部分：药物发现，材料科学和农药。候选药物中通常含有众所周知的苯并恶唑，但通常需要调整其亲脂性和目标相互作用点。在这方面，恶唑并[4,5- b ]吡嗪是一种有吸引力的杂环骨架，因为它具有更高的水溶性和两个额外的氢键受体。我们在这里报告了一个新的Pd（II）催化的多米诺反应，该反应包括N-（2-氯-3-3-杂芳基）芳基酰胺的第一个Pd（II）辅助分子内环化，并通过将其应用于2的首次合成来验证其价值。取代的恶唑啉[4,5-b ]吡嗪。我们证明了多米诺反应进行需要双齿磷配体以及芳族氮原子的存在。该方法的鲁棒性通过合成23种2-取代的恶唑并[4,5- b ]吡嗪类似物而得到了很好的证实，其产率高至高，并且在反应的芳基酰胺上同时包含吸电子和供电子取代基。
• [EN] FUSED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2012018909A1

  公开（公告）日：2012-02-09

  The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1'): wherein, Ring A' represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1' represents (1) wherein, R1a' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, -S-, -0-, -CO-, an optionally substituted methylene group, or -NRa'- (Ra' represents a hydrogen atom, or an optionally substituted C1-6 alkyl group), and Ring B1' represents an optionally further substituted 6- to 10- membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L' and R1a' may be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, R1b' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2' represents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D' represents an optionally further substituted 5- or 6- membered ring, R2' represents a hydrogen atom, or a substituent, X' represents =N- or =CRb'- (Rb' represents a hydrogen atom, or a substituent), _ _ _ _ _ represents that Rb' and R2' may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X' is =CRb'-, or a salt thereof.

  本发明提供了一种具有PDE 10A抑制作用的化合物，可用作预防或治疗精神分裂症等疾病的药物。化合物的结构如下（1'）：其中，环A'代表可选择取代的吡啶环、可选择取代的吡啉环、嘧啶环或吡嗪环，R1'代表（1）其中，R1a'代表可选择取代的苯基或可选择取代的5-至10-成员杂环基，环B2代表键、-S-、-O-、-CO-、可选择取代的亚甲基基团或-NRa'-（Ra'代表氢原子或可选择取代的C1-6烷基基团），环B1'代表可选择进一步取代的6-至10-成员芳香碳氢环、或可选择进一步取代的5-至10-成员芳香杂环环，或者，L'和R1a'可以结合形成可选择取代的双环或三环融合杂环基，或（2）其中，R1b'代表可选择取代的苯基或可选择取代的5-至10-成员杂环基，环B2'代表可选择取代的苯环、可选择取代的吡啶环、可选择取代的嘧啶环、可选择取代的吡嗪环或可选择取代的吡啉环，环D'代表可选择进一步取代的5-或6-成员环，R2'代表氢原子或取代基，X'代表=N-或=CRb'-（Rb'代表氢原子或取代基），_ _ _ _ _代表Rb'和R2'可能形成，与它们各自相邻的碳原子和氮原子一起，当X'为=CRb'-时，形成可选择取代的5-至7-成员环，或其盐。
• BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF
  申请人：BARNES David Weninger

  公开号：US20120028969A1

  公开（公告）日：2012-02-02

  The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.

  本发明提供了式(I)的化合物；或其药学上可接受的盐，其中变量如本文所定义。本发明提供了一种制造式(I)化合物的方法，它们的治疗用途，与其他药理活性剂的组合，以及药物组成。
• [EN] CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MACROCYCLIQUES ENTIÈREMENT SYNTHÉTIQUES ET À CONFORMATION CONTRAINTE
  申请人：POLYPHOR AG

  公开号：WO2013139697A1

  公开（公告）日：2013-09-26

  The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1 ) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

  公式（I）的构象受限、空间定义明确的大环环形系统由三个不同的分子部分构成：模板A、构象调制剂B和桥梁C。由该环系统I描述的大环可通过溶液中的并行合成或组合化学，或者在固相上制造。它们被设计用来与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，对酶的抑制活性或抗菌活性。特别是，这些大环显示对第1亚型内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃肽3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。
• Sulfonamide compound
  申请人：Matsubara Koki

  公开号：US20090048223A1

  公开（公告）日：2009-02-19

  A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R 3 )(R 4 )— (R 3 and R 4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G 4 represents hydroxyl group (Y is a single group), or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.

  由以下化学式表示的化合物：[A代表含氮饱和环；m表示0到2的整数；n表示1到4的整数；G1代表氢原子、氯原子、羟基、烷氧基或氨基；G2代表卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；G3代表氢原子、卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；Y代表单键，或-C(R3)(R4)-（R3和R4代表氢原子、烷基或烷烯基，它们结合在一起形成饱和碳氢环基）；G4代表羟基（Y是单个基），或-N(R1)(R2)（R1和R2代表氢原子、烷基、芳基、烯基、炔基、饱和杂环基、烷基磺酰基、酰基或胺基）；G5是A的环构成碳原子上的取代基，代表氢原子、氟原子或烷基]或其盐、或作为前药的衍生物，其强力抑制Rho激酶。